Verona Pharma PLC Block Listing Application and Review (0879E)

TIDMVRP

RNS Number : 0879E

Verona Pharma PLC

03 May 2017

Verona Pharma plc

("Verona Pharma" or the "Company")

Block Listing Application and Review

3 May 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, today announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 2,183,491 ordinary shares of GBP0.05 each to be admitted to trading on AIM as an extension of the block listing issued in respect of ordinary shares of GBP0.05 each (the "Ordinary Shares") which may arise pursuant to the exercise of warrants issued in connection with the placing completed in July 2016 (the "2016 Warrant Shares") as announced on 29 July 2016.

The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its block listing facility (all figures relate to Ordinary Shares in the table below):

 
 Name of company:                                                                              Verona Pharma plc 
--------------------------------------------------------------------------------------  ------------------------------ 
 Name of scheme:                                                                              2016 Warrant Shares 
--------------------------------------------------------------------------------------  ------------------------------ 
 Period of return:                                            From:                      29/07/2016   To:   03/05/2017 
-----------------------------------------------------------  -------------------------  -----------  ----  ----------- 
 Number and class of securities not issued/allotted under scheme(s) from previous 
  return (following 
  50/1 share consolidation announced on 08/02/2017):                                              10,262,879 
--------------------------------------------------------------------------------------  ------------------------------ 
 Plus: The amount by which the block scheme(s) has been increased since the date of 
  the last 
  return (if any increase has been applied for):                                                   2,183,491 
--------------------------------------------------------------------------------------  ------------------------------ 
 Less: Number of securities issued/allotted under scheme(s) during period:                             0 
--------------------------------------------------------------------------------------  ------------------------------ 
 Equals: Balance under scheme(s) not yet issued/allotted at end of period:                        12,446,370 
--------------------------------------------------------------------------------------  ------------------------------ 
 Number and class of share(s) (amount of stock/debit securities) originally admitted       10,262,879 on 29/07/2016 
 and the 
 Date of Admission: 
--------------------------------------------------------------------------------------  ------------------------------ 
 Total number of shares in issue at the end of the period:                                        99,014,164 
--------------------------------------------------------------------------------------  ------------------------------ 
 
 
 
 Name of contact:                    Claire Poll 
------------------------------  -------------------- 
 Telephone number of contact:    +44 (0)20 3283 4200 
------------------------------  -------------------- 
 Date:                               03/05/2017 
------------------------------  --------------------

-Ends-

For further information please contact:

 
  Verona Pharma plc                                             Tel: +44 (0)20 3283 4200 
   Jan-Anders Karlsson, Chief Executive Officer 
 
   N+1 Singer                                                    Tel: +44 (0)20 7496 3000 
   Aubrey Powell / James White/ Alex Laughton-Scott 
 
   FTI Consulting                                                Tel: +44 (0)20 3727 1000 
   Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins

Notes to Editors

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRSSMFDDFWSELI

(END) Dow Jones Newswires

May 03, 2017 09:49 ET (13:49 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024